港股异动丨国药科技逆势大涨逾8%两日飙升近30%
格隆汇7月22日丨国药科技股份(08156.HK)近期走势向上,继上个交易日大涨近18%后,今日继续逆势上涨,两日累计飙升近30%。现报0.395港元,涨8.22%,暂成交1276万港元,最新总市值16.23亿港元。

国药科技股份(08156.HK)18日晚公告,截至公告日,公司与国药药材股份有限公司及中维华信基金管理有限公司签订战略合作框架协议。
董事会相信,此次合作,将可预见为集团的彩票及“互联网+健康”业务提供巨大的潜在发展的市场空间。
值得注意的是,6月初,公司拟斥5000万港元收购一家香港现代化中医诊所集团25%权益。通过此次收购,集团进一步战略性地开展“互联网+健康”业务。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.